Bronchodilation induced by PGE(2) is impaired in Group III pulmonary hypertension

Ozen G. , Benyahia C., Mani S., Boukais K., Silverstein A. M. , Bayles R., ...More

BRITISH JOURNAL OF PHARMACOLOGY, 2019 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume:
  • Publication Date: 2019
  • Doi Number: 10.1111/bph.14854


Background and Purpose In patients with pulmonary hypertension (PH) associated with lung disease and/or hypoxia (Group III), decreased pulmonary vascular tone and tissue hypoxia is therapeutically beneficial. PGE(2) and PGI(2) induce potent relaxation of human bronchi from non-PH (control) patients via EP4 and IP receptors, respectively. However, the effects of PGE(2)/PGI(2) and their mimetics on human bronchi from PH patients are unknown. Here, we have compared relaxant effects of several PGI(2)-mimetics approved for treating PH Group I with several PGE(2)-mimetics, in bronchial preparations derived from PH Group III and control patients. Experimental Approach Relaxation of bronchial muscle was assessed in samples isolated from control and PH Group III patients. Expression of prostanoid receptors was analysed by western blot and real-time PCR, and endogenous PGE(2), PGI(2), and cAMP levels were determined by ELISA. Key Results Maximal relaxations induced by different EP4 receptor agonists (PGE(2), L-902688, and ONO-AE1-329) were decreased in human bronchi from PH patients, compared with controls. However, maximal relaxations produced by PGI(2)-mimetics (iloprost, treprostinil, and beraprost) were similar for both groups of patients. Both EP4 and IP receptor protein and mRNA expressions were significantly lower in human bronchi from PH patients. cAMP levels significantly correlated with PGI(2) but not with PGE(2) levels. Conclusion and Implications The PGI(2)-mimetics retained maximal bronchodilation in PH Group III patients, whereas bronchodilation induced by EP4 receptor agonists was decreased. Restoration of EP4 receptor expression in airways of PH Group III patients with respiratory diseases could bring additional therapeutic benefit.